Given with a beta-lactam antibiotic to provide effective treatment, have structural similarity with the beta-lactam antibiotics and function as substrate of beta-lactamase, thus reducing harm on the beta-lactam antibiotic (e.g. clavulanic acid, sulbactam, tazobactam)
Vancomycin
Binds to D-Ala-D-Ala terminal of growing peptide chain, usually ineffective against gram-negative bacteria, used to treat methicillin-resistant Staphylococcus aureus (MRSA)
Inhibitors of protein synthesis
Aminoglycosides bind to 30S ribosomal subunit
Macrolide-lincosamide-streptogramin (MLS) group bind to 50S ribosomal subunit
Ketolides bind to 50S ribosomal subunit
Oxazolidinones bind to 50S ribosomal subunit
Chloramphenicol binds 50S ribosomal subunit
Tetracyclines bind 30S ribosomal subunit
Glycylglycines bind to 30S ribosomal subunit
Abelardo B. Aguilar, a Filipino scientist, was "supposed to be" the discoverer of a powerful macrolide antibiotic erythromycin, but the pharmaceutical company Eli Lilly and Company filed for the patent and was granted in 1953
Inhibitors of DNA/RNA synthesis
Fluoroquinolones inhibit DNA synthesis by binding DNA gyrases
Metronidazole causes breakage of DNA strands
Rifampin inhibits RNA synthesis by binding DNA-dependent, RNApolymerase
Inhibitors of other metabolic processes
Nitrofurantoin may have several bacterial enzyme targets and directly damage DNA
Polymyxins disrupt cell membrane
Sulfonamides interfere with folic acid pathway by binding the enzyme dihydropteroate synthase
Trimethoprim interferes with folic acid pathway by binding the enzyme dihydrofolate reductase
Anti-tuberculosis drugs
Rifampicin
Isoniazid
Pyrazinamide
Ethambutol
Streptomycin
Synergism
Occurs when the antimicrobial activity of a combination of antimicrobial agents is greater than the activity of the individual agents alone
Antimicrobial resistance
Ability of a microbe to resist effects of medication, may be environmentally-mediated or microorganism-mediated (intrinsic or acquired)
Biologic resistance
Organism becomes less susceptible
Clinical resistance
Susceptibility has been lost, drug is no longer effective
Impermeability
Inability to penetrate the cell wall of bacteria, related to lipopolysaccharide and outer membrane proteins (porins)
Biofilms
Decreased penetration of antibiotics, decreased oxygen and nutrients, formation of persister cells
Efflux
Efflux pumps remove toxic substances from the cell
Enzymatic inactivation
Beta-lactamases hydrolyze beta-lactam antibiotics, extended-spectrum beta-lactamases (ESBLs) can hydrolyze even newly developed beta-lactams
Target site modification
Chromosomal mutations in penicillin-binding proteins (PBPs) or enzymatic alteration of ribosomal targets
Acquisition of new targets
Acquire cellular targets with reduced affinity for the antibiotic, e.g. methicillin-resistant Staphylococcus aureus (MRSA)
Timeline of development of antibiotics vs. resistance
Antimicrobial susceptibility testing
Test performed on bacteria isolated from clinical specimens to determine which antimicrobial agents might be effective in treating infections
Conventional susceptibility testing methods
Dilution tests (broth dilution, agar dilution)
Diffusion tests (disk agar diffusion, gradient diffusion)
Broth dilution method
Serial dilution of antibiotic is prepared, and to each tube a standard amount of inoculum is added, determines MIC and can determine MBC
Minimum Inhibitory Concentration (MIC)
Lowest concentration of antibiotic that inhibits growth
Minimum Bactericidal Concentration (MBC)
Lowest concentration of antibiotic that kills 99.9% of bacteria
Susceptibility testing
Also known as Antimicrobial Sensitivity Testing
Purpose of susceptibility testing
Test performed on bacteria isolated from clinical specimens to determine which antimicrobial agents might be effective in treating infections caused by the bacteria
Conventional susceptibility testing methods
Dilution tests
Diffusion tests
Broth dilution method
Serial dilution of antibiotic is prepared, and to each tube a standard amount of inoculum is added